Ieq Capital LLC Has $343,000 Holdings in Solventum Corporation $SOLV

Key Points

• Ieq Capital LLC reduced its stake in Solventum Corporation by 77.1%, owning 4,515 shares worth $343,000 after selling 15,160 shares in the first quarter.
• Multiple hedge funds, including Ameriprise Financial and BNP Paribas, increased their investments in Solventum during the fourth quarter, indicating growing institutional confidence.
• Wall Street analysts have generally positive expectations for Solventum, with recent upgrades leading to a consensus rating of "Hold" and an average target price of $85.75.

Ieq Capital LLC lowered its stake in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 77.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,515 shares of the company's stock after selling 15,160 shares during the period. Ieq Capital LLC's holdings in Solventum were worth $343,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Concurrent Investment Advisors LLC bought a new stake in shares of Solventum during the 1st quarter worth approximately $216,000. Bessemer Group Inc. raised its stake in shares of Solventum by 17.1% during the 1st quarter. Bessemer Group Inc. now owns 1,963 shares of the company's stock worth $150,000 after purchasing an additional 287 shares in the last quarter. Comerica Bank raised its stake in Solventum by 39.7% in the 1st quarter. Comerica Bank now owns 77,725 shares of the company's stock valued at $5,910,000 after acquiring an additional 22,079 shares during the period. CW Advisors LLC bought a new stake in Solventum in the 1st quarter valued at $312,000. Finally, Raymond James Financial Inc. boosted its position in Solventum by 12.0% during the first quarter. Raymond James Financial Inc. now owns 315,099 shares of the company's stock worth $23,960,000 after purchasing an additional 33,790 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms have commented on SOLV. Wells Fargo & Company lifted their price objective on shares of Solventum from $75.00 to $79.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. KeyCorp began coverage on shares of Solventum in a research report on Friday, June 6th. They set a "sector weight" rating for the company. Morgan Stanley raised shares of Solventum from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $80.00 to $103.00 in a research report on Tuesday, July 15th. Piper Sandler reiterated an "overweight" rating and set a $94.00 price objective (up previously from $87.00) on shares of Solventum in a research report on Friday, August 8th. Finally, Argus upgraded Solventum from a "hold" rating to a "buy" rating and set a $90.00 price objective on the stock in a research report on Tuesday, July 1st. Four investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Solventum currently has an average rating of "Hold" and an average price target of $85.11.

Solventum Stock Performance

SOLV stock traded up $2.52 during trading hours on Thursday, hitting $73.74. 1,425,913 shares of the stock were exchanged, compared to its average volume of 1,297,221. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. Solventum Corporation has a 12 month low of $60.70 and a 12 month high of $85.92. The firm has a market capitalization of $12.79 billion, a P/E ratio of 34.14, a P/E/G ratio of 2.91 and a beta of 0.53. The company has a 50-day simple moving average of $73.18 and a two-hundred day simple moving average of $72.73.

Solventum (NYSE:SOLV - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, beating analysts' consensus estimates of $1.45 by $0.24. The business had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.12 billion. Solventum had a return on equity of 29.93% and a net margin of 4.52%.Solventum's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.